The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Management of patients with penta-class refractory myeloma
Amrita Krishnan, MD, City of Hope, Duarte, CA, emphasizes the importance of understanding the underlying reasons for patients with multiple myeloma (MM) becoming penta-class refractory in order to address the unmet treatment need for this patient population. Refractoriness may stem from a loss of target or compromised T-cell health, so targeting different markers or administering drugs to restore T-cell fitness are potential strategies to overcome this. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock Options/Ownership-Public Company: Bristol-Myers Squibb Company
Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Takeda Pharmaceuticals USA Inc
Contracted Research: Janssen Biotech
Consultancy: Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company, GlaxoSmithKline, Regeneron Pharmaceuticals Inc, Sanofi Genzyme
Advisory Committee: Sutro Biopharma
